The initial success of the copyright undeniably reshaped the drug landscape, but placing funds in companies primarily reliant on unbranded versions presents a challenging picture. Although early returns were impressive, the expiration of patents and the rise of cheaper alternatives have diminished the customer base. Thus, a thorough assessment of p